4 recent drug approvals

Here are four FDA drug or treatment approvals Becker’s has covered since Nov. 15, starting with the most recent:

Advertisement

1. Apretude — Apretude was approved as the first injectable treatment for HIV preexposure prevention, or PrEP. 

2. Pafolacianine — Pafolacianine, which goes by the brand name Cytalux, is an imaging drug that has been approved to help surgeons better identify cancerous ovarian tissue when operating. 

3. Besremi — PharmaEssentia Corp.’s Besremi has been approved for the treatment of a rare blood disease called polycythemia vera, which affects about 6,200 people in the U.S. annually. 

4. Voxzogo — BioMarin’s Voxzogo has been approved as the first drug designed to treat short stature caused by achondroplasia, the most common form of dwarfism. 

The FDA approved 46 new drugs in 2021, including 16 cancer drugs. To view the full list, click here

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.